Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAIN-PAD: orforglipron once daily in symptomatic peripheral artery disease with intermittent claudication
CTR20254736Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of orforglipron in arteriosclerosis obliterans, sponsored by Eli Lilly and Company. Started Jan 2026; status: active.
02
Drugs
orforglipron
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on CTR20254736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254736.